Satyavrat Shukla

Satyavrat Shukla

Former President and Chief Executive OfficeratSpero Therapeutics· In proxies 2022–2025

Pay in FY2025+4% from the year before · Spero Therapeutics stock +126.2% the same year

Satyavrat Shukla was paid $2.0M in FY2025 (Dec), up 4%. Spero Therapeutics stock rose 126.2% that year.

Pay$100 in the stock at the end of FY21 → $15
Pay is from the Summary Compensation Table of each Spero Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Spero TherapeuticsPublic company · 4 yr
    • Former President and Chief Executive Officer2022 – Present · 4 yrStock in role -92%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?